Johnson & Johnson picked up a plant in Vacaville, California, nearly 20 years ago with its $10.5 billion buyout of Alza, a deal that also gave it attention-deficit disorder drug Concerta and cancer drug Doxil. Janssen is now focused in other areas and has decided the plant is no longer needed.
Nearly 50 employees are slated to be let go next week, according to a California WARN notice (PDF), as J&J’s pharmaceutical unit Janssen begins a three-year phaseout, a spokesman said in an email. The company declined to say how many total employees work there.
J&J says the closure is part of an effort to rework its manufacturing network as its drug portfolio changes.
“As part of this transformation, we will scale down production at our Vacaville, California facility with the intent to fully exit the site by the end of 2022,” J&J spokesman Matthew Johnson said.
Janssen, like other drugmakers, is putting more effort into areas such as immunology that involve biologic drugs. In the fourth quarter, sales of its Stelara worldwide grew by 33.6% on the back of its launch in Crohn’s disease, while psoriasis drug Tremfya has nabbed a 6.6% share of an ultracompetitive U.S. market since its July 2017 debut.
By Eric Palmer
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.